Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Visit http://www.ecancer.org for more

Prof Margolese (The Jewish General Hospital, McGill University, Montreal, Canada) presents, at a press conference at ASCO 2015, a federally funded phase III trial suggests that postmenopausal women with ductal carcinoma in situ (DCIS) may have an additional option for breast cancer prevention.

• Categoria